BRAF and neoplasm: The newly utilized keywords included “bevacizumab”, “acquired–resistance”, “BRAF”, “monotherapy”, “vitiligo”, “mutational–landscape”, “mismatch–repair deficiency”, “treatment discontinuation”, “tumor–infiltrating lymphocytes (TILs)”, and “antibiotics”.